Expression of membrane type 1 matrix metalloproteinase is associated with cervical carcinoma progression and invasion

Cancer Research

Volumn 65, Issue 15, 2005, Pages 6543-6550

  Zhai, Yali ^a   Hotary, Kevin B ^a   Nan, Bin ^b   Bosch, F Xavier ^c   Muñoz, Nubia ^d   Weiss, Stephen J ^a   Cho, Kathleen R ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN SCHOOL OF PUBLIC HEALTH   (United States)

^c HOSPITAL DURAN I REYNALS   (Spain)

^d Instituto Nacional de Cancerología   (Colombia)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 1; GELATINASE A; MATRIX METALLOPROTEINASE 14; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ARTICLE; CANCER GROWTH; CANCER INVASION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN SITU HYBRIDIZATION; KERATINOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CARCINOMA IN SITU; WART VIRUS;

CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CERVICAL INTRAEPITHELIAL NEOPLASIA; DISEASE PROGRESSION; FEMALE; HELA CELLS; HUMANS; IN SITU HYBRIDIZATION; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASES, MEMBRANE-ASSOCIATED; METALLOENDOPEPTIDASES; NEOPLASM INVASIVENESS; TISSUE INHIBITOR OF METALLOPROTEINASE-2; UTERINE CERVICAL NEOPLASMS;

EID: 23044466812     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-0231     Document Type: Article

References (59)

1. Parkin DM, Pisani P, Ferlay J. Global cancer statistics. CA Cancer J Clin 1999;49:33-64,
2. Münger K, Baldwin A, Edwards KM, et al. Mechanisms of human papillomavirus-induced oncogenesis. J Virol 2004;78:11451-60.
3. Östör AG. Natural history of cervical intraepithelial neoplasia-a critical review. Int J Gynecol Pathol 1993; 12:186-92.
4. Shah KV, Kessis TD, Shah F, Gupta JVV, Shibata DK, Jones RW. Human papillomavirus investigation of patients with cervical intraepithelial neoplasia 3, some of whom progressed to invasive cancer. Int J Gynecol Pathol 1996;15:127-30.
5. Kiviat NB, Critchlow CW, Kurman RJ. Reassessment of the morphological continuum of cervical intraepithelial lesions: does it reflect different stages in the progression to cervical carcinoma? In: Muñoz N, Bosch FX, Shah KV, Meheus A, editors. The epidemiology of cervical cancer and human papillomavirus. IARC: Lyon; 1992. p. 59-66.
6. John A, Tuszynski G. The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis. Pathol Oncol Res 2001;7:14-23.
7. Liotta LA, Steeg PS, Stetler-Stevenson WG, Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 1991;64:327-36.
8. Crawford HC, Matrisian LM. Tumor and stromal expression of matrix metalloproteinases and their role in tumor progression. Invasion Metastasis 1994; 14:234-45.
9. Freije JM, Balbin M, Pendas AM, Sanchez LM, Puente XS, Lopez-Otin C. Matrix metalloproteinases and tumor progression. Adv Exp Med Biol 2003;532:91-107.
10. Davidson B, Goldberg I, Gotlieb WH, et al. High levels of MMP-2, MMP-9, MT1-MMP and TIMP-2 mRNA correlate with poor survival in ovarian carcinoma. Clin Exp Metastasis 1999;17:799-808.
11. Pacheco MM, Mourao M, Mantovani EB, Nishimoto IN, Brentani MM. Expression of gelatinases A and B, stromelysin-3 and matrilysin genes in breast carcinomas: clinico-pathological correlations. Clin Exp Metastasis 1998;16:577-85.
12. Davies B, Waxman J, Wasan H, et al. Levels of matrix metalloproteases in bladder cancer correlate with tumor grade and invasion. Cancer Res 1993;53:5365-9.
13. Davidson B, Goldberg I, Kopolovic J, et al. MMP-2 and TIMP-2 expression correlates with poor prognosis in cervical carcinoma-a clinicopathologic study using immunohistochemistry and mRNA in situ hybridization. Gynecol Oncol 1999;73:372-82,
14. Mitra A, Chakrabarti J, Chattopadhyay N, Chatterjee A. Membrane-associated MMP-2 in human cervical cancer. J Environ Pathol Toxicol Oncol 2003;22:93-100.
15. Asha Nair S, Karunagaran D, Nair MB, Sudhakaran PR. Changes in matrix metalloproteinases and their endogenous inhibitors during tumor progression in the uterine cervix. J Cancer Res Clin Oncol 2003;129:123-31.
16. Murphy G, Knauper V, Cowell S, et al. Evaluation of some newer matrix metalloproteinases. Ann N Y Acad Sci 1999;878:25-39.
17. Pei D, Weiss SJ. Transmembrane-deletion mutants of the membrane-type matrix metalloproteinase-1 process progelatinase A and express intrinsic matrix-degrading activity. J Biol Chem 1996;271:9135-40.
18. Ohuchi E, Imai K, Fujii Y, Sato H, Seiki M, Okada Y. Membrane type 1 matrix metalloproteinase digests interstitial collagens and other extracellular matrix macromolecules. J Biol Chem 1997;272:2446-51.
19. Seiki M. Membrane-type 1 matrix metalloproteinase: a key enzyme for tumor invasion. Cancer Lett 2003; 194:1-11.
20. Sato H, Takino T, Okada Y. et al. A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature 1994;370:61-5.
21. Strongin AY, Collier I, Bannikov G, Marmer BL, Grant GA, Goldberg GI. Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease. J Biol Chem 1995;270:5331-8.
22. Ellerbroek SM, Stack MS. Membrane associated matrix metalloproteinases in metastasis. Bioessays 1999;21:940-9.
23. Lehti K, Lohi J, Juntunen MM, Pei D, Keski-Oja J. Oligomerization through hemopexin and cytoplasmic domains regulates the activity and turnover of membrane-type 1 matrix metalloproteinase. J Biol Chem 2002;277:8440-8.
24. Seiki M, Yana I. Roles of pericellular proteolysis by membrane type-1 matrix metalloproteinase in cancer invasion and angiogenesis. Cancer Sci 2003;94: 569-74.
25. Toth M, Bernardo MM, Gervasi DC, et al. Tissue inhibitor of metalloproteinase (TIMP)-2 acts synergistically with synthetic matrix metalloproteinase (MMP) inhibitors but not with TIMP-4 to enhance the (membrane type 1)-MMP-dependent activation of pro-MMP-2. J Biol Chem 2000;275:41415-23.
26. Will H, Atkinson SJ, Butler GS, Smith B, Murphy G. The soluble catalytic domain of membrane type 1 matrix metalloproteinase cleaves the propeptide of progelatinase A and initiates autoproteolytic activation. Regulation by TIMP-2 and TIMP-3. J Biol Chem 1996; 271:17119-23.
27. Hotary KB, Allen ED, Brooks PC, Datta NS, Long MW, Weiss SJ. Membrane type I matrix metalloproteinase usurps tumor growth control imposed by the three-dimensional extracellular matrix. Cell 2003;114:33-45.
28. Lehti K, Lohi J, Valtanen H, Keski-Oja J. Proteolytic processing of membrane-type-1 matrix metalloproteinase is associated with gelatinase A activation at the cell surface. Biochem J l998;334:345-53.
29. Zhao H, Bernardo MM, Osenkowski P, et al. Differential inhibition of membrane type 3 (MT3)-matrix metalloproteinase (MMP) and MT1-MMP by tissue inhibitor of metalloproteinase (TIMP)-2 and TIMP-3 regulates pro-MMP-2 activation. J Biol Chem 2004;279:8592-601.
30. Sheu BC, Lien HC, Ho HN, et al. Increased expression and activation of gelatinolytic matrix metalloproteinases is associated with the progression and recurrence of human cervical cancer. Cancer Res 2003;63:6537-42.
31. Okada A, Bellocq JP, Rouyer N, et al. Membrane-type matrix metalloproteinase (MT-MMP) gene is expressed in stromal cells of human colon, breast, and head and neck carcinomas. Proc Natl Acad Sci U S A 1995; 92:2730-4.
32. Polette M, Nawrocki B, Gilles C, et al. MT-MMP expression and localisation in human lung and breast cancers. Virchows Arch 1996;428:29-35.
33. Nakada M, Nakamura H, Ikeda E, et al. Expression and tissue localization of membrane-type 1, 2, and 3 matrix metalloproteinases in human astrocytic tumors. Am J Pathol 1999;154:417-28.
34. Nomura H, Sato H, Seiki M, Mai M, Okada Y. Expression of membrane-type matrix metalloproteinase in human gastric carcinomas. Cancer Res 1995;55: 3263-6.
35. Gilles C, Polette M, Piette J, et al. High level of MT-MMP expression is associated with invasiveness of cervical cancer cells. Int J Cancer 1996;65:209-13.
36. Yoshizaki T, Sato H, Maruyama Y, et al. Increased expression of membrane type 1-matrix metalloproteinase in head and neck carcinoma. Cancer 1997;79:139-44.
37. Iwasaki M, Nishikawa A, Fujimoto T, et al. Anti-invasive effect of MM1-166, a new selective matrix metalloproteinase inhibitor, in cervical carcinoma cell lines. Gynecol Oncol 2002;85:103-7.
38. Yamamoto M, Mohanam S, Sawaya R, et al. Differential expression of membrane-type matrix metalloproteinase and its correlation with gelatinase A activation in human malignant brain tumors in vivo and in vitro. Cancer Res 1996;56:384-92.
39. Muñoz N, Bosch FX de Sanjose S, et al. The causal link between human papillomavirus and invasive cervical cancer-a population-based case-control study in Colombia and Spain. Int J Cancer 1992;52:743-9.
40. Bosch FX, Muñoz N, de Sanjose S, et al. Risk factors for cervical cancer in Colombia and Spain. Int J Cancer 1992;52:750-8.
41. Connolly DC, Greenspan DL, Wu R, et al. Loss of fhit expression in invasive cervical carcinomas and intraepithelial lesions associated with invasive disease. Clin Cancer Res 2000;6:3505-10.
42. Kaur P, McDougall JK. HPV-18 immortalization of human keratinocytes. Virology 1989;173:302-10.
43. Garrett LR, Perez-Reyes N, Smith PP, McDougall JK. Interaction of HPV-18 and nitrosomethylurea in the induction of squamous cell carcinoma. Carcinogenesis 1993;14:329-32.
44. De Geest K, Turyk ME, Hosken MI, Hudson JB, Laimins LA, Wilbanks GD. Growth and differentiation of human papillomavirus type 31b positive human cervical cell lines. Gynecol Oncol 1993;49:303-10.
45. Kolligs FT, Hu G, Dang CV, Fearon ER. Neoplastic transformation of RK3E by mutant β-catenin requires deregulation of Tcf/Lef transcription but not activation of c-myc expression. Mol Cell Biol 1999;19:5696-706.
46. Hotary K, Allen E, Punturieri A, Yana I, Weiss SJ. Regulation of cell invasion and morphogenesis in a three-dimensional type I collagen matrix by membrane-type matrix metalloproteinases 1, 2, and 3. J Cell Biol 2000;149:1309-23.
47. Le J, Dauchot P, Perrot JL, Cambazard F, Frey J, Chamson A. Quantitative zymography of matrix metalloproteinases by measuring hydroxyproline: application to gelatinases A and B. Electrophoresis 1999;20:2824-9.
48. Ueda M, Ueki M, Terai Y, et al. Stimulatory effects of EGF and TGF-α on invasive activity and 5′-deoxy-5-fluorouridine sensitivity in uterine cervical-carcinoma SKG-IIIb cells. Int J Cancer 1997;72:1027-33.
49. Ueda M, Fujii H, Yoshizawa K, et al. Effects of EGF and TGF-α on invasion and proteinase expression of uterine cervical adenocarcinoma OMC-4 cells. Invasion Metastasis 1998;18:176-83.
50. Rosenthal EL, Johnson TM, Allen ED, Apel IJ, Punturieri A, Weiss SJ. Role of the plasminogen activator and matrix metalloproteinase systems in epidermal growth factor- and scatter factor-stimulated invasion of carcinoma cells. Cancer Res 1998;58:5221-30.
51. Sato T, Iwai M, Sakai T, et al. Enhancement of membrane-type 1-matrix metalloproteinase (MT1-MMP) production and sequential activation of progelatinase A on human squamous carcinoma cells co-cultured with human dermal fibroblasts. Br J Cancer 1999;80:1137-43.
52. Kondapaka SB, Fridman R, Reddy KB. Epidermal growth factor and amphiregulin up-regulate matrix metalloproteinase-9 (MMP-9) in human breast cancer cells. Int J Cancer 1997;70:722-6.
53. Ueno H, Nakamura H, Inoue M, et al. Expression and tissue localization of membrane-types 1, 2, and 3 matrix metalloproteinases in human invasive breast carcinomas. Cancer Res 1997;57:2055-60.
54. Sabeh F, Ota I, Holmbeck K, et al. Tumor cell traffic through the extracellular matrix is controlled by the membrane-anchored coUagenase MT1-MMP. J Cell Biol 2004;167:769-81.
55. Masson V, de la Ballina LH, Munaut C, et al. Contribution of host MMP-2 and MMP-9 to promote tumor vascularization and invasion of malignant keratinocytes. FASEB J 2005;19:234-6.
56. Nakada M, Yamada A, Takino T, et al. Suppression of membrane-type 1 matrix metalloproteinase (MMP)-mediated MMP-2 activation and tumor invasion by testican 3 and its splicing variant gene product, N-Tes. Cancer Res 2001;61:8896-902.
57. Rhee JS, Coussens LM. RECKing MMP function: implications for cancer development. Trends Cell Biol 2002;12:209-11.
58. Uekita T, Gotoh I, Kinoshita T, et al. Membrane-type 1 matrix metalloproteinase cytoplasmic tail-binding protein-1 is a new member of the Cupin superfamily. A possible multifunctional protein acting as an invasion suppressor down-regulated in tumors. J Biol Chem 2004;279:12734-43.
59. Parat MO, Anand-Apte B, Fox PL. Differential caveolin-1 polarization in endothelial cells during migration in two and three dimensions. Mol Biol Cell 2003;14:3156-68.